Welcome to our dedicated page for Nevro news (Ticker: NVRO), a resource for investors and traders seeking the latest updates and insights on Nevro stock.
Nevro Corp. (NYSE: NVRO) is a global medical device company headquartered in Redwood City, California and focused on technologies for chronic pain treatment. This news page aggregates company announcements, financial updates and clinical evidence related to Nevro’s proprietary 10 kHz spinal cord stimulation (SCS) therapy and sacroiliac (SI) joint fusion offerings.
Investors and observers can follow Nevro’s regular disclosures on quarterly and full-year financial results, including worldwide and U.S. revenue, international revenue, operating performance and cash position. The company also issues updates on strategic matters, such as its announced definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction, which remains subject to shareholder and regulatory approvals and other customary conditions.
Because Nevro operates in chronic pain management, a significant portion of its news flow highlights clinical and product developments. These include publications of data on 10 kHz SCS in painful diabetic neuropathy and Type 2 diabetes, showing durable pain relief and reported improvements in measures such as HbA1c, weight and sleep, as well as biomechanical studies of the Nevro1 SI Joint Fusion System. Product and regulatory updates, such as CE Mark Certification in Europe for the HFX iQ SCS system and launches of HFX iQ with HFX AdaptivAI, also feature prominently.
In addition, Nevro regularly announces employee inducement equity awards under NYSE Rule 303A.08, reflecting hiring activity, and provides commentary on commercial execution, restructuring efforts and marketing initiatives. For anyone tracking NVRO, this news feed offers a centralized view of Nevro’s financial performance, clinical evidence, product expansion and corporate transactions over time.
Nevro Corp. and Boston Scientific Corp. have resolved their intellectual property litigation through a settlement. This agreement allows Boston Scientific to operate with its current products utilizing features below 1,500 Hz while granting Nevro similar freedoms. Nevro will license paresthesia-free therapy technology to Boston Scientific, and vice versa. The settlement also includes a net payment of $85 million from Boston Scientific to Nevro, concluding all ongoing litigations between the two parties.
Nevro Corp. (NYSE: NVRO), a medical device company based in Redwood City, California, will have CFO Rod MacLeod present at the Canaccord Genuity 42nd Annual Growth Conference. The event is scheduled for August 10, 2022, at 2:30 pm Eastern Time, in Boston, MA. Investors can access a live webcast and subsequent recording on Nevro's website. Nevro specializes in innovative solutions for chronic pain, including the proprietary 10 kHz Therapy, which has benefited over 80,000 patients worldwide. For more details, visit www.nevro.com.
Nevro Corp. (NVRO), a global medical device company, will report its financial results for Q2 2022 after market close on August 3, 2022. A conference call to discuss the results will take place at 1:30 pm PT / 4:30 pm ET. Investors can tune in by calling (888) 330-2443 or +1 (240) 789-2728 with Conference ID: 3583097. Nevro specializes in innovative solutions for chronic pain, including its proprietary 10 kHz Therapy, impacting over 80,000 patients globally. For further updates, visit Nevro's website.
Nevro Corp. (NYSE: NVRO) reported 12-month results from the SENZA-PDN trial, showing extensive pain relief and significant improvements in health-related quality of life (HRQoL) for patients with painful diabetic neuropathy (PDN) treated with 10 kHz spinal cord stimulation. Key findings include a 2.5- to 4.5-fold improvement in HRQoL metrics compared to minimal clinical importance, with over 70% of patients indicating better overall health. The data supports the product's potential for expanding market access and payer coverage, with a total addressable market of approximately $3.5 billion to $5.0 billion.
Nevro Corp. (NYSE: NVRO) announced positive results from the SENZA-PDN trial at the ADA 82nd Scientific Sessions. The 24-month follow-up demonstrated that 10 kHz spinal cord stimulation (SCS) therapy provides significant pain relief for patients with painful diabetic neuropathy (PDN). Key findings include an 84% responder rate, a 77% average reduction in pain, and 89% patient satisfaction. The study involved 216 patients across 18 U.S. centers, marking it as the largest RCT of its kind. Nevro plans to release additional data in Q4 2022 and anticipates expanding treatment options for PDN patients.
Nevro Corp. (NYSE: NVRO) announced that the SENZA Painful Diabetic Neuropathy (PDN) Randomized Controlled Trial data will be presented at the ADA's 82nd Scientific Sessions from June 3-7, 2022. The presentation will include 24-month follow-up results from the trial, which compares Nevro's 10 kHz spinal cord stimulation (SCS) therapy plus medical management to standard care. Previous results showed significant pain relief and improved quality of life. Nevro anticipates complete 24-month data availability in Q4 2022 for further presentation.
Nevro Corp. (NYSE: NVRO) reported first-quarter 2022 revenue of $87.8 million, a 1% decline from the previous year but a 7% increase compared to 2019. U.S. trial and permanent implant procedures grew by 10% and 2% respectively. The company experienced a net loss from operations of $32.8 million. For Q2 2022, Nevro expects revenues between $103 million and $106 million, and maintains full-year guidance of $415 million to $430 million. Positive payer coverage from UnitedHealthcare and Noridian could enhance access to its therapies.
Nevro Corp. (NYSE: NVRO) will report its first quarter 2022 financial results after market close on May 4, 2022. Following the report, management will host a conference call at 1:30 PM PT / 4:30 PM ET to discuss the results. Interested investors can dial (888) 330-2443 in the U.S. or +1 (240) 789-2728 internationally, using Conference ID: 3583097. The call will be accessible via a live webcast and archived on Nevro's website, www.nevro.com.
Nevro Corp. announced an update from Noridian, the Medicare Administrative Contractor, which includes two new ICD-10 codes for Painful Diabetic Neuropathy (PDN) effective retroactively from January 1, 2022. This update increases access to Nevro's 10 kHz Therapy for PDN patients, expanding coverage from approximately 25% to 43% of PDN patients in the U.S. Noridian oversees Medicare coverage in several Western states. Nevro's CEO stated that this advancement will facilitate better access and is working to ensure further coverage by other payers.
Nevro Corp. reported a 4Q 2021 revenue of $102.8 million, down 6% year-over-year and 10% from 2019. The net loss was $26.2 million, with a non-GAAP adjusted EBITDA of - $7.5 million. U.S. revenue decreased 7% to $88.4 million, while international revenue fell 5% to $14.3 million. For 2022, Nevro projects first quarter revenue of $85-$87 million and annual revenue of $415-$430 million, anticipating impacts from COVID-19. Additionally, it received FDA approval for a new therapy and a positive coverage decision from UnitedHealthcare.